Curatis Holding AG (SWX:CURN)

Market Cap	85.06M +35.7%
Revenue (ttm)	13.50M +32.8%
Net Income	-658.00K
EPS	-0.13
Shares Out	5.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,253
Open	16.75
Previous Close	16.80
Day's Range	16.00 - 16.75
52-Week Range	11.05 - 27.90
Beta	-0.64
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 22, 2026

About Curatis Holding AG

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collage...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 9
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: CURN

Financial Performance

In 2025, Curatis Holding AG's revenue was 10.80 million, an increase of 56.61% compared to the previous year's 6.90 million. Losses were -1.42 million, -67.41% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error